JP2020530300A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530300A5
JP2020530300A5 JP2020507589A JP2020507589A JP2020530300A5 JP 2020530300 A5 JP2020530300 A5 JP 2020530300A5 JP 2020507589 A JP2020507589 A JP 2020507589A JP 2020507589 A JP2020507589 A JP 2020507589A JP 2020530300 A5 JP2020530300 A5 JP 2020530300A5
Authority
JP
Japan
Prior art keywords
gpa
variant
cleaved
seq
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020507589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530300A (ja
JP7744621B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/046196 external-priority patent/WO2019032952A1/en
Publication of JP2020530300A publication Critical patent/JP2020530300A/ja
Publication of JP2020530300A5 publication Critical patent/JP2020530300A5/ja
Application granted granted Critical
Publication of JP7744621B2 publication Critical patent/JP7744621B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020507589A 2017-08-11 2018-08-10 切断されたモルモットｌ－アスパラギナーゼバリアントおよび使用の方法 Active JP7744621B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762544411P 2017-08-11 2017-08-11
US201762544396P 2017-08-11 2017-08-11
US62/544,396 2017-08-11
US62/544,411 2017-08-11
PCT/US2018/046196 WO2019032952A1 (en) 2017-08-11 2018-08-10 TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE

Publications (3)

Publication Number Publication Date
JP2020530300A JP2020530300A (ja) 2020-10-22
JP2020530300A5 true JP2020530300A5 (enExample) 2021-09-24
JP7744621B2 JP7744621B2 (ja) 2025-09-26

Family

ID=63405429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020507589A Active JP7744621B2 (ja) 2017-08-11 2018-08-10 切断されたモルモットｌ－アスパラギナーゼバリアントおよび使用の方法

Country Status (8)

Country Link
US (1) US11578315B2 (enExample)
EP (1) EP3664832B1 (enExample)
JP (1) JP7744621B2 (enExample)
CN (1) CN111050784B (enExample)
AU (1) AU2018313253B2 (enExample)
CA (1) CA3106549A1 (enExample)
ES (1) ES2965372T3 (enExample)
WO (1) WO2019032952A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114292853A (zh) * 2021-11-29 2022-04-08 国药集团动物保健股份有限公司 Sumo促溶表达标签及其应用、sumo促溶表达蛋白、重组菌株及蛋白的制备方法
CN114369173B (zh) * 2022-03-22 2022-07-08 中国农业科学院北京畜牧兽医研究所 一种利用融合蛋白标签促进人颗粒溶素及动物NK lysin在毕赤酵母中表达的方法
CN116459344B (zh) * 2023-04-28 2025-03-18 上海市生物医药技术研究院 一种MNSFβ/RC3H1 PPI干扰多肽的抗炎治疗应用
WO2025026424A1 (en) * 2023-08-02 2025-02-06 The Hong Kong Polytechnic University Bioengineered asparaginase fusion proteins
WO2025210068A1 (en) 2024-04-03 2025-10-09 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Activity-improved variants of human asparaginase 1

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE9002213D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Albumin binding proteins
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
JP3721210B2 (ja) * 1995-02-08 2005-11-30 株式会社林原生物化学研究所 哺乳類のｌ−アスパラギナーゼをコードするｄｎａ
JP3819540B2 (ja) * 1996-06-07 2006-09-13 株式会社林原生物化学研究所 Ｌ−アスパラギナーゼ活性を有する哺乳類由来のポリペプチド
US6537547B1 (en) 1996-06-07 2003-03-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptides having L-asparaginase activity
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
WO2004112717A2 (en) * 2003-06-17 2004-12-29 Harrison Roger G Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
EP1654379A4 (en) 2003-06-26 2007-01-17 Lifesensors Inc METHOD AND COMPOSITIONS FOR IMPROVED PROTEIN EXPRESSION AND CLEANING
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
WO2007103290A2 (en) 2006-03-03 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods directed to asparagine synthetase and asparaginase therapies
EP1894940A1 (en) * 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
JP6088246B2 (ja) * 2009-08-15 2017-03-01 ジェネンテック， インコーポレイテッド 以前に治療された乳癌の治療のための抗血管新生療法
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012170640A1 (en) 2011-06-07 2012-12-13 The Trustees Of Columbia University In The City Of New York Methods and compositions for trail-drug combination therapy
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
CN103184208B (zh) * 2011-12-27 2015-09-16 拜奥生物科技（上海）有限公司 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用
ES2670442T3 (es) 2012-05-25 2018-05-30 Janssen Biotech, Inc. Dominios de unión a albúmina de consenso no naturales
NO2776305T3 (enExample) 2014-04-23 2018-01-27

Similar Documents

Publication Publication Date Title
JP2020530300A5 (enExample)
JP2019509041A5 (enExample)
SA521430398B1 (ar) Ph20 تركيبة صيدلانية، تشمل متغير ودواء هيالورونيداز البشرى، للحقن تحت الجلد
JP2023144018A5 (enExample)
JP2020534352A5 (enExample)
JP2017018125A5 (enExample)
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
EP2964761B1 (en) Pharmaceutical composition comprising albumin-binding arginine deiminase for cancer targeting treatment
JP2019536462A5 (enExample)
JP2018522563A5 (enExample)
Pokrovskaya et al. Recombinant intracellular Rhodospirillum rubrum L-asparaginase with low L-glutaminase activity and antiproliferative effect
JP2020508685A5 (enExample)
JP2004511201A5 (enExample)
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
AR065075A1 (es) Vectores para la expresion multiple de genes
MY204458A (en) Tertiary amino lipidated cationic peptides for nucleic acid delivery
JP2008514618A5 (enExample)
JP2013172743A5 (enExample)
MX2009002612A (es) Modoficaciones de péptidos derivados de cupredoxinas y métodos de uso de los mismos.
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
JP2003533186A5 (enExample)
JPWO2019156137A5 (enExample)
JP2018537089A5 (enExample)
FI4069729T3 (fi) Optimoidut muokatut meganukleaasit, joilla on spesifisyys tunnistussekvenssiä varten hepatiitti b -virusgenomissa